Mark T. Osterman, MD, MSCE

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine

Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease. Gastroenterology 2017 Notes: Oral presentation at annual Digestive Diseases Week meeting May 2017.

Papamichael K, Osterman MT, Cheifetz AS: Reply. Clinical Gastroenterology and Hepatology 15: 1638-9, 2017.

Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive versus reactive therapeutic drug monitoring of infliximab in inflammatory bowel disease. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.

Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive compared to reactive therapeutic drug monitoring of infliximab is associated with less IBD-related surgery and hospitalization. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 15: 1197-9, 2017.

Osterman MT, Foley C, Matthias I: Clozapine-induced acute gastrointestinal necrosis: a case report. Journal of Medical Case Reports 11: 270, 2017.

Osterman MT: Ready or not, here they are: Anti-TNF biosimilars for IBD. AGA Perspectives 13: 12-3, 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 2017 Notes: In press.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology 15: 1580-8, 2017.

Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. Gastroenterology 2017 Notes: Poster presentation for annual Digestive Diseases Week meeting, Chicago IL, May 2017.

back to top
Last updated: 11/22/2017
The Trustees of the University of Pennsylvania